263 results on '"Mansoor, W."'
Search Results
2. Uncovering the Potential of Indoor Localization: Role of Deep and Transfer Learning
3. The UK National Oesophagogastric Multidisciplinary Team Meeting: An Initiative From the UK & Ireland Oesophagogastric Group
4. Exploiting 2-D Representations for Enhanced Indoor Localization: A Transfer Learning Approach
5. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
6. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
7. 1249P Older patients experience similar toxicity and survival outcomes to FLOT chemotherapy compared to younger patients
8. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
9. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours
10. PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma
11. DISPERSAL OF HYDROGEN IN THE RETINA—A THREE-LAYER MODEL
12. Pulmonary function test physiology and progression in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (dipnech): P141
13. Older patients enrolling in early phase clinical trials; higher rates of sarcopenia, but no increase in toxicity
14. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours
15. 1192P Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
16. PD-0541: Transfer learning for automatic sarcopenia evaluation at T12 vertebral level
17. 589P The impact of sarcopenia in patients enrolled in early phase cancer trials
18. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
19. A painful blistering rash on the lower legs and perineum
20. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
21. Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study
22. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
23. A comparison of diagnostic and management pathways for patients with nung neuroendocrine tumors in ENETS Centres of Excellence vs non-accredited centres in the UK: Results from the National Lung NET pathway Project (‘LEAP’)
24. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
25. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
26. Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study
27. Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
28. Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence
29. Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study
30. Prognostic importance of lymph node (LN) yield after curative resection of gastroenteropancreatic neuroendocrinetumours (GEP NETs)
31. EGFR amplification (amp) and survival in the REAL-3 trial
32. Association of sarcopenia with dose-limiting toxicties and survival in oesophageal adenocarcinoma treated with neoadjuvant chemotherapy
33. Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the functional assessment of anorexia cachexia therapy anorexia/cachexia subscale (FAACT A/CS)
34. TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
35. SIOG2021-0045 - Older patients enrolling in early phase clinical trials; higher rates of sarcopenia, but no increase in toxicity
36. Supplementary Material for: 68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management
37. 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience
38. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
39. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
40. Reliability and latency trade-off in time domain interleaving for OFDM communication systems
41. Neoadjuvant FLOT: Real world toxicity from a specialist UK centre
42. The incidence, diagnostic pathway and management of pulmonary carcinoid tumours in the UK: results from the National Lung NET pathway (‘LEAP’) Project
43. Attitudes and knowledge of clinicians and dieticians towards cancer nutrition in a tertiary referral oncology centre
44. P141 Pulmonary function test physiology and progression in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (dipnech)
45. Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study
46. Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life
47. Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence
48. A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
49. Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration
50. Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.